Case Study 09 – Urothelial Carcinoma
Patient: 66 years – Male diagnosed with High grade urothelial papillary carcinoma Clinical Testing: Treatment Options: In general CDKN2A deficient
OneCell Diagnostics is now 1Cell.Ai
Patient: 66 years – Male diagnosed with High grade urothelial papillary carcinoma Clinical Testing: Treatment Options: In general CDKN2A deficient
Patient: 68 years – Female diagnosed with Intrahepatic Cholangiocarcinoma Clinical Testing: Treatment Options: MEK Inhibitor (Binimetinib) treatment can be used
Patient: 69 years – Male diagnosed with Adenocarcinoma-Gallbladder Clinical Testing: Treatment Options: As per the NCCN recommendations ERBB2 mutations benefit
Patient: 54 years – Male diagnosed with Squamous cell carcinoma of Buccal Mucosa Clinical Testing: Treatment Options: Overall preclinical and
Patient: 52 years – Male diagnosed with Adenocarcinoma Lung with Brain metastasis Clinical Testing: Treatment Options: Osimertinib is standard of
Patient: 54 years – Female diagnosed with Recurrent Metastatic Ovarian Adenocarcinoma Clinical Testing: Treatment Options: Co-occurring mutations in BRAF and
Patient: 67 years – Male diagnosed with Well-Differentiated Adenocarcinoma of Stomach Clinical Testing: Treatment Options: Various pre-clinical and clinical trials
Patient: 48 years – Female diagnosed with left breast cancer Clinical Testing: Treatment Options: The presence of HER2 amplification suggests
Patient: 52 years – Female diagnosed with Signet Ring Cell Adenocarcinoma of Colon Clinical Testing: Treatment Options: The presence of
Shaping the Future of Precision Oncology From Barcelona, 1Cell.Ai joined global leaders at ESMO 2024 to showcase our latest innovations